Breast Cancer Meeting Highlights [Archive] - Page 2

Consistent High False Negative Rate of HER2 qRT-PCR of Oncotype DX® (0 replies)
Changes in Gene Expression after One Dose of Trastuzumab (0 replies)
Early decrease in CTC level = response to Tykerb & Capecetibine in Her2+ brain mets (0 replies)
T-DM1 and Pertuzumab as New Tools for HER2 Specific Antibody-Therapy (0 replies)
Adipose Tissue in Breast Cancer: an Active Participant in Breast Cancer Progression (0 replies)
Zoledronic Acid Reverses the Epithelial-Mesenchymal Transition (0 replies)
The Cytotoxicity of Select Neutrophils in Cancer Patients (0 replies)
Adjuvant Therapy in Patients with a Borderline HER-2 Status (0 replies)
Novel Approaches to Breast Cancer Management in Low-Income Countries (0 replies)
SABCS 2011 - videos + (4 replies)
SABC on Cure (1 replies)
Nov. 17 CancerConnect - CIM - Ask the expert (0 replies)
Upcoming conferences in Sweden (0 replies)
2011 ASCO Podcasts (0 replies)
ASCO 2011 from CURExtra (0 replies)
New Directions in the Treatment of Patients With HER2-positive Breast Cancer (3 replies)
St. Gallen Endocrine classifications and recurrence (0 replies)
Impact of a change of body mass index following adjuvant tx (0 replies)
Long-term responders to trastuzumab (0 replies)
Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer (2 replies)
Protection of adjuvant trastuzumab in sites of early relapses (0 replies)
Good results for small tumors tx with Herceptin (0 replies)
Oncotype returns high false negative of Her2 results (2 replies)
ASCO 2011 abstracts available (1 replies)
Effects of bc protection of pregnancy on Her2- vs Her2+ bc (6 replies)
PTEN deletion: An underlying mechanism for PTEN loss in breast cancer (0 replies)
Enhancement of trastuzumab selectivity via cyclic complex formation (0 replies)
Lab Model of Lapatinib Resistance (0 replies)
Serotonin signaling plays a role in regulation of autophagy in breast cancer cells (3 replies)
In vitro cell and in vivo animal studies of the demethylating agent in treating HER2+ (0 replies)
Overcoming trastuzumab resistance with the irreversible Pan-HER inhibitor neratinib (0 replies)
Regulation of Her-2 in long-term letrozole resistant cells by HSP-90 (0 replies)
Night work and breast cancer risk: CECILE study (0 replies)
Sustained release curcumin microparticles show promise as chemopreventive against HER (0 replies)
Curcumin suppresses the expression of HER-2 gene (0 replies)
Amplification of tumor immunity with cryoablation (0 replies)
HER2/neu positive receptor status is associated with a low DNA repair capacity in bc (0 replies)
A difference of HER-2 amplification index between luminal B and HER2 enriched subgrou (0 replies)
Epigenetic portraits of human breast cancers (0 replies)
Effects of aerobic training to improve cardiovascular function after chemo (0 replies)
Exposure to gefitinib during premalignant risk window/lifelong protection to MMTV mic (0 replies)
Entosis: Adhesion, autophagy, and murder (0 replies)
Autophagy and HER2 interaction in mammary tumorigenesis (0 replies)
Heat shock protein vaccines for immunotherapy of Her-2/neu positive breast cancers (0 replies)
Signaling networks potentially involved in breast cancer metastasis to the brain (0 replies)
Short-term pregnancy levels of estradiol delays Her-2+ mammary tumor development (0 replies)
Delphinidin dietary anthocyanidin modulates EGFR/HER-2 signaling pathway in bc cells (0 replies)
Endoxifen exhibits anti-tumor activity in Her2+, tamox resistant tumors in lab (1 replies)
Biomarkers of Response to Herceptin + Chemo (0 replies)
Research on reversing Herceptin resistance (0 replies)
Social isolation stress-induced obesity increases mammary cancer risk (0 replies)
Combating trastuzumab resistance by targeting Src (0 replies)
Metformin potentiates the efficacy of radiotherapy (0 replies)
Targeting Her2 - Podcasts from SABCS (0 replies)
'Aging in the know' from Health In Aging (0 replies)
c4yw (0 replies)
Targeting Her2: Beyond Trastuzumab (2 replies)
Phase I study of a Her2/Her3 heterodimer drug (0 replies)
Phase II study of T-DM1 + PI3K Inhibitor (0 replies)
Evidence for Treatment of Metastatic Breast Cancer beyond 2nd Line (0 replies)
Phase II Multicenter Study of Docetaxel and Bevacizumab (Bev) +/- Trastuzumab for MBC (0 replies)
Use of Selective COX-2 Inhibitors and Breast Cancer Recurrence (0 replies)
Dual Estrogen Effects on Breast Cancer (0 replies)
Oral Contraceptive Use and Overall Breast Disease Risk (0 replies)
Insulin Resistance, Diabetes Mellitus and Breast Cancer and moderate exercise (0 replies)
Relationship between Vitamin D Deficiency and Breast Cancer Histology (0 replies)
Resolving the problem of intra tumoral Her2 heterogeneity (1 replies)
Next-Generation Transcriptome Sequencing of the Normal Breast (0 replies)
Could We Reduce the Number of Exams in the Follow-Up of Breast Cancer Survivors (0 replies)
Seroma Formation Is Associated with Lymphedema-Related Symptoms (0 replies)
Impact of Adjuvant Trastuzumab on Local Regional Recurrence (0 replies)
Patterns of Relapse According to Subtypes in LNN BC (0 replies)
Symptom Burden of patients receiving chemo + Herceptin improves when chemo stops (0 replies)
Concurrent vs. Sequential Administration of Adjuvant Trastuzumab (0 replies)
Investigating Early Features of Aromatase Inhibitor-Induced Arthralgia (0 replies)
Cognitive Effects of Endocrine Therapy in Patients with Breast Cancer (7 replies)
ER Positive Screen Detected Breast Cancers Do Not Require Chemotherapy (0 replies)
Evaluating the Efficacy of chemo in postmeno ER+ pts (1 replies)
BreastCancerTrials.org: Nationwide Clinical Trial Matching Service (0 replies)
Truncated ERBB2 Receptors: Diagnostic and Therapeutic Targets (0 replies)
Increase of Coronary Artery Stenosis after Radiation for Breast Cancer (0 replies)
HERA subset analysis: effect of age on Her2+ outcomes (0 replies)
Correlation of Oncotype Dx Recurrence Score and Luminal Subtypes of Breast Cancer (0 replies)
False Positive HER-2 Testing by Fluorescence In Situ Hybridization (0 replies)
Fat cells regulate bc functions differently in lean and obese women (0 replies)
Study: Higher BMI predicts poor neoadj response among Her2+ (0 replies)
Plasticity of the ER and HER2 Signaling Networks (0 replies)
Heat Shock Protein 90 Inhibitors: New Targeted Therapy To Overcome AI Resistance (0 replies)
Lapatinib Resistance Confers Cross-Resistance to Microtubule Inhibitors (1 replies)
Hormone-Receptor Expression and Activity of Trastuzumab-Based Therapy (0 replies)
BMI related to effectiveness of extended AI therapy (0 replies)
Weight loss in high risk postmeno women alters serum biomarkers assc w/bc (0 replies)
Competing Causes of Mortality vs. Breast Cancer Mortality (0 replies)
Sentinel Node Trial: outcomes for micro and macro node mets (0 replies)
Drug Development – Targeting HER2 beyond Trastuzumab (0 replies)
Tumor Remissions under Trastuzumab Therapy (0 replies)
Can Resistance to Trastuzumab Be Reversed by Endocrine Therapy? (1 replies)
In the Lab: Development of a Her2 targeted anthracycline (1 replies)
Responses to Subsequent Anti-HER2 Therapy after Treatment with T-DM1 (0 replies)
Efficacy and Safety of Neratinib (HKI-272) in Combination with Paclitaxel (1 replies)
Study of the best sequence for administration of Tykerb and AI's (0 replies)
Increased Rate of HER2-Positive Breast Cancers among Women w/Germline TP53 Mutations (2 replies)
LACE Study: Vitamin use and bc outcomes (0 replies)
Aspirin Use and the Risk of Breast Cancer (0 replies)
Early Detection of Recurrent Breast Cancer Using Metabolite Profiling (0 replies)
Consistent Prognostic Impact of HER2 Status Over Time (0 replies)
PR- bc patients have poorer outcomes when tx with SERMs (0 replies)
Androgen Receptor Expression in BC related to outcomes (0 replies)
Influence of Body Mass Index on Presence of Disseminated Tumor Cells (0 replies)
Using Serum Her2 levels to monitor response to neoadj chemo (1 replies)
In Lab: Curcumin active against Her2 and may overcome Herceptin Resistance (1 replies)
Phase II Trial Administering a HER2/neu-Derived Peptide vaccine w/Herceptin (0 replies)
Metronomic Chemotherapy Inhibits Tumor Growth and Metastases Development in mice (1 replies)
Factors Associated with Job Resumption after Primary Breast Cancer Treatment (0 replies)
How Common Is Sexual Dysfunction among Women with Early Stage Breast Cancer? (0 replies)
Circadian Clock Genes predict neoadj chemo response (0 replies)
Anti-Herceptin antibodies associated with longer PFS in Herceptin tx pts (0 replies)
Study sugguests ER+ P13K activated tumors have strong Herceptin response (0 replies)
Ki67 Discriminates Luminal A & B BC better than Her2 status (0 replies)
Her2+ BC account for large portion of Mammographic Failure to detect (0 replies)
Discordant Pet scans (ER & Gloucose) predicts ER insensitivity in Her2+ Stage IV pts (1 replies)
Tykerb + Fulvestrant not useful in Her2+ ER+ metastatic pts. tx w/AI (0 replies)
Lab Findings: Tykerb + Insulin/Insulin-like growth factor receptor for ER resistance (0 replies)
Lab Findings: T-DM1 + PK13 inhibitor shows promise for Her2+ bc (0 replies)
Discordance in Hormone Receptor and HER2 Status in BC during Tumor Progression (0 replies)
Herceptin + Pertuzumab active in Her2+ bc w/o chemo - NeoSphere study (0 replies)
Online Conference San Antonio Breast Cancer Symposium (0 replies)
Her2+ Correlates to Coexisting Invasion in DCIS (0 replies)
Multi-Modality tx improves brain met survival (0 replies)
Brain Met outcomes for Her2+ patients enrolled in LEAP (0 replies)
Her2+ patients Retain an Immunological Proficiency Compromised in Her2- cases (0 replies)
TN and Her2 bc more chemo sensitive but have higher rate of brain mets (0 replies)
Phase II trial of 4 drug combination for early Her2+ bc (0 replies)
Neoadjuvant trial of Concurrent Trastuzumab and Paclitaxel without Anthracycline (0 replies)
Response to neoadjuvant chemo + Herceptin predicts survival (0 replies)
No anti-tumor effects seen in adding Zolendraic acid to chemo (1 replies)
Retesting Her2 status in metastatic patients cost effective and relevant (0 replies)
Short-term exposure to pregnancy level ER delays Her2+ tumor development (0 replies)
Short-term exposure to pregnancy ER levels alters bc pathway development (0 replies)
Safety of High Dose Vitamin D in pre-meno women (0 replies)
Chinese Herb Fructus Cornii prevents ER+ BC in the lab (0 replies)
Protective Effect of Dietary Intervention limited to high baseline Testosterone (0 replies)
Omega-3 Fatty Acids for Chemoprevention (0 replies)
Tamoxifen, Flaxseed and Tumor Growth (4 replies)
Molecular Biomarkers for Resistance to Trastuzumab (0 replies)
BC Stem Cells survive Herceptin by downregulation of Her2 (0 replies)
Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients (0 replies)
High baseline inflammatory signature results in lower response to AI's (0 replies)
Impact of BMI on endocrine tx in postmeno HR+ BC (0 replies)
Obesity at Dx associated with worse outcomes in HR+ BC (0 replies)
CYP2D6 metabolism unrelated to Tamoxifen benefit (0 replies)
FIRST study: Arimdex vs. Fulvestrant for Advanced BC (0 replies)
Colon cancer risk (2 replies)
The role of autophagy inhibition as a neoadjuvant therapy for DCIS (0 replies)
Adjuvant trastuzumab therapy in tumors smaller than 1 cm (0 replies)
Is it safe to use transtuzumab for the treatment of breast cancer during pregnancy? (0 replies)
The prognostic and predictive impact of BMI on clinical outcome of HER2-positive bc (5 replies)
Evaluation of trastuzumab without chemotherapy as a postoperative adjuvant therapy (0 replies)
A phase I study to assess the safety, tolerability, and PK of ARRY-380, an oral HER2 (0 replies)
Estrogen receptor positivity in normal breast epithelium from women with breast cance (0 replies)
Subcutaneous testosterone-anastrozole implant therapy in breast cancer survivors (1 replies)
Correlation between diabetes and ER/HER2 status in African Americans (0 replies)
Survival after supraclavicular recurrence of breast cancer (0 replies)
Can whole-brain irradiation (WBRT) be replaced by radiosurgery? (0 replies)
Breast cancer at the extremes of age: Predicting recurrence and mortality (0 replies)
Long-term outcome of node-negative early breast cancer patients (0 replies)
Molecular predictive factors of response to taxanes (T) and anthracyclines (A) in bc (0 replies)
Is microcalcification on mammography relrelated to bone metastasis & bad prognosis? (0 replies)
In situ carcinoma (ISC) accompanying small (≤ 1 cm) invasive breast carcinoma (IBC) (0 replies)
Genomic profile of screen- and symptom-detected breast cancers and association w/ DFS (0 replies)
Association of phosphorylated-HER2 with relapse in patients (0 replies)
Is age an independent predictor of survival and time to recurrence in breast cancer? (0 replies)
A couple ASCO 2010 related links (3 replies)
Method of detection of DCIS to predict HER2 overexpression (0 replies)
Impact of BMI on clinical outcome of HER2-positive breast cancer (0 replies)
Circulating tumor cells (CTCs) and association with survival in molecular subtypes (1 replies)
Survival benefit of neck dissection for patients w/bc w/supraclavicurlar LN mets (2 replies)
Safety and efficacy of low-dose metronomic chemotherapy with capecitabine (1 replies)
Early detection of recurrent breast cancer using metabolite profiling (0 replies)
Biomarker changes associated with the development of resistance to AIs (0 replies)
Discordance in hormone receptor status in breast cancer during tumor progression (0 replies)
Should liver metastases of breast cancer be biopsied to improve treatment choice? (0 replies)
False-negative HER2 tests with appropriate positive controls (0 replies)
Tykerb treatment for DCIS - study (0 replies)
HER2+ gene expression signature specific for trastuzumab resistance and poor prognosi (0 replies)
Good news for triple positive (ER+/PR+/Her2+) bc (1 replies)
Cause-specific and all-cause mortality of HER2-positive, node-negative, T1a & T1b bc (0 replies)
For T1a,b,N0M0 Her2+ patients not treated with chemo or Herceptin, age at dx importan (0 replies)
Association of gene copy number alterations with prognostic subtypes (0 replies)
Gene signature of metformin actions on primary breast cancer (0 replies)
Dose-dependent interaction between tamoxifen and antidepressants on patient complianc (0 replies)
Beta-blockers and ACE inhibitors in the prevention of trastuzumab-related cardiotoxic (0 replies)
CK-19 mRNA-positive CTCs and Herceptin treatment (0 replies)
Ovarian suppression + endocrine therapy + zoledronic acid in premeno bc patients (0 replies)
ASCO: Leptin & High BMI May Reduce Her2+ Survival (2 replies)
What ASCO Can Tell You About Biotechs (0 replies)
Statistics from Peru for DFS and OS in Her2+ & ER+/- BC (6 replies)
Correlation of molecular and clinically distinct phenotypes in HER2+ ER+ BC (0 replies)
Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer (0 replies)
Treatment by subtype: a neoadjuvant study (0 replies)
June 2010: Updates from the 2010 ASCO Annual Meeting (0 replies)
2010 ASCO Abstracts (0 replies)
Breast carcinoma DNA methylation profiles associated w/tumor size, alcohol & folate (1 replies)
Plasma coenzyme Q10 levels and postmenopausal breast cancer risk (0 replies)
Molecular markers for breast carcinogenesis models induced by environment & ER (0 replies)
Potential of PET imaging to predict the response to anti-HER2 therapy in breast cance (0 replies)
Cyclin E amplification, a novel mechanism of resistance to trastuzumab in HER2+ bc (0 replies)
Temporal changes of gene expression in bc cells during adaptation to ER deprivation (0 replies)
FOXO1A is a target for HER2 overexpressing breast tumors (0 replies)
Metformin enhances tumor regression and reduces tumor burden in mice (0 replies)
Mammotrophic hormone score and risk of postmenopausal breast cancer (0 replies)
Urine biomarkers outperform serum biomarkers in the diagnosis of various human cancer (0 replies)
Autophagy inhibition in endocrine resistant human breast cancer cell lines (0 replies)
Gene expression profiling of hormone-regulating pathways (0 replies)
Salivary biomarkers for breast cancer detection (0 replies)
Circadian disruption and breast carcinogenesis (0 replies)
Gene expression profiling in circulating cells (CTCs) a tool for early mets detection (0 replies)
Aromatase expression promotes breast cancer tumorigenesis and bone metastasis (0 replies)
Newly designed nanobioconjugate for tx of Her2+ bc (1 replies)
M1 is a candidate proteasome activator drug in breast cancer that down-regulates Her2 (0 replies)
Proteomics-based characterization of pathways involved in tamoxifen resistance (0 replies)
Paradoxical actions of a c-Src inhibitor on long-term ER deprived cells (1 replies)
Expression patterns of the ERBB2 gene and associations with breast risk and survival (0 replies)
Alternate mechanisms of PI3K pathway activation among subtypes of DCIS (0 replies)
Copy number variation in low- and high-grade breast tumors (0 replies)
14-3-3zeta cooperates with ErbB2 in DCIS to invasive bc progression (0 replies)
Activation of mTOR in obesity persists after weight loss (0 replies)
High expression of CXCL13 was associated with lower risk for relapse in Her2+ BC (0 replies)
Curcumin analogues are cytotoxic towards ER- BC lines (1 replies)
Obese mice that lose weight retain higher bc risk via mTOR pathway (0 replies)
Hypoxia regulates the breast cancer stem/progenitor cell population (0 replies)
Building an accelerated path to tailored adjuvant cancer therapy (0 replies)
Molecular basis of correlation between HER2+ and sensitivity to anthracyclines (0 replies)
Heat shock protein 90 inhibitors: New mode of therapy to overcome AI resistance (0 replies)
MiR-21 upregulation in breast cancer cells leads to PTEN loss and Herceptin resistanc (0 replies)
Deletion of cyclooxygenase-2 in mouse mammary epithelial cells delays bc onset (0 replies)
Intermittent treatment of ER+ BC with exemestane: Translational research (0 replies)
Body fat %, inflammation, and bc survival (0 replies)
gene expression profiles reveals subtype-specific drug sensitivities among bc lines (0 replies)
Diabetes pharmacotherapy: A potential modifier of breast cancer prognosis? (0 replies)
Cyclin D1 regulaties progesterone receptor expression (0 replies)
Leptin-induced breast cancer cell migration requires upregulation of survivin (0 replies)
The topography of estrogen receptor expression in the human breast (0 replies)
Breast cancer stem cells play a role in trastuzumab resistance in mouse models (0 replies)
Chloroquine + Her2 inhibitors = growth inhibition (0 replies)
HER2 expression occurs early in breast cancer dissemination (0 replies)
ASCO (Dec. 2009) Reports (0 replies)
Video and audio from SABC 2009 (and more) (2 replies)
Fatty Acid Synthase (FASN) as a Therapeutic Target for Breast Cancer Metastasis (0 replies)
Outcomes of Stereotactic Radiosurgery in Her2+ brain mets (0 replies)